Get the Stockscreener App
0.6306
12.31%
-0.0885
After Hours:
.63
-0.0006
-0.10%
Vincerx Pharma Inc stock is traded at $0.6306, with a volume of 977.66K.
It is down -12.31% in the last 24 hours and down -50.35% over the past month.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.
See More
Previous Close:
$0.7191
Open:
$0.6687
24h Volume:
977.66K
Relative Volume:
0.85
Market Cap:
$1.41M
Revenue:
-
Net Income/Loss:
$-48.85M
P/E Ratio:
-0.273
EPS:
-2.31
Net Cash Flow:
$-46.25M
1W Performance:
-22.05%
1M Performance:
-50.35%
6M Performance:
-95.49%
1Y Performance:
-99.50%
1-Day Range:
$0.591
$0.70
1-Week Range:
$0.591
$1.22
52-Week Range:
$0.591
$151.80
Vincerx Pharma Inc Stock (VINC) Company Profile
Name
Vincerx Pharma Inc
Sector
Industry
Phone
650-800-6676
Address
260 SHERIDAN AVENUE, PALO ALTO
Compare VINC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
0.6306 | 1.41M | 0 | -48.85M | -46.25M | -2.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-22 | Initiated | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-21 | Initiated | SVB Leerink | Outperform |
| Sep-13-21 | Initiated | Laidlaw | Buy |
| Aug-25-21 | Initiated | B. Riley Securities | Buy |
Vincerx Pharma Inc Stock (VINC) Latest News
Such Is The Power Of Vincerx Pharma Inc (NASDAQ: VINC) - Stocks Register
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - GlobeNewswire
VINC stock touches 52-week low at $0.73 amid sharp annual decline - Investing.com UK
Vincerx Pharma Plans Reverse Merger With AI Infrastructure Firm QumulusAI -March 18, 2025 at 09:40 am EDT - Marketscreener.com
Vincerx Pharma plans reverse merger with QumulusAI - Investing.com
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - Benzinga
Vincerx Pharma's $300M AI Transformation: QumulusAI Merger Creates New Computing Powerhouse - StockTitan
Vincerx Pharma Plunges After Scrapping Reverse Merger With Oqory And Vivaso - Nasdaq
Vincerx Pharma terminates reverse merger term sheet and evaluates strategic alternatives - MSN
Vincerx Pharma Terminates Reverse Merger Deal With Oqory - MarketWatch
Vincerx Pharma Explores Strategic Alternatives Post Merger Termination - TipRanks
Vincerx Pharma Announces Termination Of Reverse Merger Term Sheet -February 28, 2025 at 04:12 pm EST - Marketscreener.com
Vincerx Pharma announces termination of reverse merger term sheet - TipRanks
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - The Manila Times
Vincerx Pharma, Inc. Terminates Reverse Merger Agreement and Will Explore Strategic Alternatives - Nasdaq
Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - StockTitan
Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update - Defense World
VINC stock touches 52-week low at $1.17 amid market challenges - Investing.com Australia
VINC stock touches 52-week low at $1.17 amid market challenges By Investing.com - Investing.com South Africa
Vincerx Pharma Regains Compliance With Nasdaq Listing Rule 5550(A)(2) -February 18, 2025 at 05:27 pm EST - Marketscreener.com
Vincerx Pharma announces reverse stock split; shares drop - MSN
VINC stock touches 52-week low at $1.3 amid market challenges - Investing.com Australia
Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Large Increase in Short Interest - MarketBeat
Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Rises By 1,022.5% - MarketBeat
VINC stock touches 52-week low at $1.62 amid market challenges - Investing.com Canada
Vincerx Pharma, Oqory highlight Phase 1a/1b data for OQY-3258 - TipRanks
Vincerx Pharma and Oqory reveal merger and cancer drug data - Investing.com
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - GlobeNewswire
Vincerx Pharma and Oqory reveal merger and cancer drug data By Investing.com - Investing.com UK
Revolutionary Cancer Treatment Achieves Unprecedented 80% Success Rate in Clinical Trial - StockTitan
Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn
Vincerx Pharma enters at-the-market equity offering deal - MSN
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn
Vincerx Pharma (NASDAQ:VINC) Stock Quotes, Forecast and News Summary - Benzinga
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Vincerx Pharma files for $100M mixed securities shelf - MSN
Vincerx Pharma (NASDAQ:VINC) Implements 1-for-20 Reverse Stock Split - Defense World
Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans - The Business Journals
Vincerx Pharma (VINC) Stock Price, News & Analysis - MarketBeat
Vincerx Pharma Inc. Announces Merger with Oqory - TipRanks
Vincerx Pharma, Inc. Announces Reverse Stock Split - The Manila Times
Vincerx Pharma Announces 1-for-20 Reverse Stock Split, Shares to Adjust January 28 - StockTitan
Vincerx Pharma enters at-the-market equity offering deal By Investing.com - Investing.com Australia
Vincerx Pharma ends sales agreement, approves reverse stock split - MSN
Vincerx Pharma Inc Stock (VINC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):